During the past decade, Nagaoka Red Cross Hospital conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 1 clinical trials were completed, i.e. on average, 16.7% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 1 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Nagaoka Red Cross Hospital" #1 sponsor was "Nagaoka Red Cross Hospital" with 6 trials, followed by "Bayer" with 1 trials sponsored, "Celgene" with 1 trials sponsored, "Chugai Pharmaceutical" with 1 trials sponsored and "Eli Lilly and Company" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Nagaoka Red Cross Hospital" #1 collaborator was "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "Gilead Sciences" with 1 trials as a collaborator, "Japan Lung Cancer Society" with 1 trials as a collaborator and "Kurume University" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Nagaoka Red Cross Hospital" are "Type 2 Diabetes Mellitus" (5 trials), "Rheumatoid Arthritis" (2 trials), "Asthma" (1 trials), "Blood Pressure" (1 trials) and "Crohn's Disease" (1 trials). Many other conditions were trialed in "Nagaoka Red Cross Hospital" in a lesser frequency.

Most popular intervention types in "Nagaoka Red Cross Hospital" are "Drug" (11 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Alogliptin" (1 trials), "BAY1213790 (Osocimab)" (1 trials), "Baricitinib" (1 trials) and "Bedaquiline" (1 trials). Other intervention names were less common.

The vast majority of trials in "Nagaoka Red Cross Hospital" are 14 trials for "All" genders.

Currently, there are NaN active trials in "Nagaoka Red Cross Hospital". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Nagaoka Red Cross Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Nagaoka Red Cross Hospital, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".